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Abstract 
 
The forkhead box M1 (FOXM1) transcription factor gene has been implicated in almost all human 
cancer types. It would be an ideal biomarker for cancer detection but, to date, its translation into a 
cancer diagnostic tool is yet to materialise. The quantitative Malignancy Index Diagnostic System 
(qMIDS) was the first FOXM1 oncogene-based diagnostic test developed for quantifying squamous 
cell carcinoma aggressiveness. The test was originally validated using head and neck squamous cell 
carcinomas (HNSCC) from European patients. The HNSCC gene expression signature across 
geographical and ethnic differences is unknown. This is the first study evaluated the FOXM1-based 
qMIDS test using HNSCC specimens donated by ethnic Chinese patients. We tested 50 Chinese 
HNSCC patients and 18 healthy subjects donated 68 tissues in total. qMIDS scores from the Chinese 
cohort were compared with the European datasets (n=228). The median±SD scores for the Chinese 
cohort were 1.13±0.66, 4.02±1.66 and 5.83±3.13 in healthy oral tissues, adjacent tumour margin and 
HNSCC core tissue, respectively. Diagnostic test efficiency between the Chinese and European 
datasets was almost identical. Consistent with previous European data, qMIDS scores for HNSCC 
samples were not influenced by gender or age. The degree of HNSCC differentiation, clinical stage 
and lymphatic metastasis status were found to be correlated with qMIDS scores. This study provided 
the first evidence that the pathophysiology of HNSCC was molecularly indistinguishable between the 
Chinese and European specimens. The qMIDS test robustly quantifies a universal FOXM1-driven 
oncogenic program, at least in HNSCC, which transcends ethnicity, age, gender and geographic 
origins. 
 
Introduction 
 
Head and neck squamous cell carcinoma (HNSCC) is affecting over half a million people worldwide 
each year [1]. Its 5-year survival rates are poor (16–29%) among patients with late stages (Stage IV 
and pN3) of HNSCC [2]. Human papilloma virus (HPV) associated HNSCC is known to have better 
prognosis compared to HPV-negative patients. However, the overall prevalence of HPV in HNSCC 
was found to be less than 25.9% [3]. According to the latest Cancer Statistics in China, there were 
approximately 135,100 new HNSCC cases and 70,700 deaths [4, 5]. Although HNSCC is not as 
common compared to esophageal cancer in China, whilst incidence and mortality rates of 
esophageal cancer are declining [6], HNSCC incidence and mortality rates are both increasing 
despite improvements in treatment modalities [4, 5]. Alarmingly, HNSCC mortality rate increases 
dramatically from age 35 to 85 by more than 65-fold despite only a moderate (11-fold) increase in 
incidence rate within this age range [4], emphasising an urgent need to identify and treat patients as 
early as possible. When comparing urban to rural areas in China, urban incidence rate was 40% 
higher than rural areas but no difference was found for mortality rates between the two areas [4], 
suggesting there may be a systemic problem in current diagnostic and/or treatment interventions that 
leads to no improvement in survival rates despite higher detection rates in the urban population. This 
is likely due to the inability to identify high-risk patients at early stages when treatment is most 
effective. The 5-yr survival for early localised cancers can exceed 80% but falls to less than 20% in 
late stage tumours especially when regional lymph nodes are involved [2]. Such data is neither 
surprising nor exclusive to China. A worldwide consensus opinion appears to be that of tumour 
heterogeneity hampering accurate diagnosis/prognostication which impacts on treatment 
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insufficiency in turns lead to high rates of tumour recurrence and no improvement in survival rates 
over the last 3 decades [7-9]. Early treatment can significantly safe long-term costs and improve 
survival by avoiding expensive, invasive head and neck surgery which often leads to debilitating 
consequences not only affects feeding, speech and vision, but may also destroy the face, disrupting 
one’s personal identity. It is well documented that improved diagnostic and prognostic accuracy to 
inform the most appropriate intervention could significantly improve patient outcome, reduce mortality 
and alleviate healthcare costs [10]. 
 
In 2013, we have developed a FOXM1-oncogene associated multi-biomarker ‘quantitative 
Malignancy Index Diagnostic System’ (qMIDS) [11] for quantifying the aggressiveness of squamous 
cell carcinoma (SCC). FOXM1 transcription factor has been shown to be amongst the top 
upregulated oncogenes across 39 cancer types and is a major predictor of poor cancer prognosis 
[12]. The qMIDS assay therefore represented the first FOXM1-based cancer diagnostic test which 
was previously validated on patients living in the UK and Norway [11]. Given that cancer is often 
heterogeneous, one marker alone would not be reliable or accurate for diagnosis. Hence, qMIDS was 
demonstrated previously to involve FOXM1 plus 13 FOXM1-associated genes (HOXA7, AURKA, 
NEK2, CCNB1, CEP55, CENPA, DNMT3B, DNMT1, HELLS, MAPK8, BMI1, ITGB1 and INV) as a 
panel of 14 biomarkers (and 2 reference genes) for quantitative diagnosis of malignancy [11]. We had 
previously shown that qMIDS test were able to quantitatively segregate between normal and 
malignancy whilst unaffected by non-malignant inflammatory condition (lichen planus). The present 
study was carried out to independently compare and evaluate the use of qMIDS assay for diagnosing 
HNSCC in non-European patients, for which we carried out a study in China involving ethnic Chinese. 
The qMIDS assay was also independently setup and performed in China to rule out bias and inherent 
technical factors. 
 
Materials and methods 
 
Patient recruitment and study protocol 
All 50 patients with HNSCC admitted from June 2014 to August 2015 were selected, 6 of these 
patients provided paired adjacent tumour margin and core HNSCC tumour specimens. In addition, 18 
healthy individuals (undergone either wisdom tooth extraction or facial restorative/reconstruction 
surgery) donated redundant normal oral mucosa tissues for this study. All patients and healthy 
individuals in this study were ethically Chinese and natives of Guizhou Province in China. All clinical 
samples were collected according to local ethical committee-approved protocols and informed patient 
consent was obtained from all participants. The study was approved by the Institution Review Board 
of Human Ethics Committee of Guizhou Medical University. For each patient, histopathological 
reports of the tissue samples were obtained from collaborating clinicians. Fresh biopsy tissues were 
preserved in RNALater (#AM7022, Ambion, Applied Biosystems, Warrington, UK) and stored short 
term at 4°C (within 1 day) before transportation and subsequent storage at -80°C until use. All tissue 
samples were digested with nuclease-free proteinase K (Roche, UK) at 55-60°C before mRNA 
extraction (Dynabeads mRNA Direct kit, Invitrogen, UK) and cDNA synthesis (Transcriptor cDNA 
Synthesis kit, Roche, UK). All samples were tested blindly to ensure that the qMIDS assays were 
performed objectively. 
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The qMIDS assay 
The qMIDS assay methodology was described previously [11]. Briefly, the qMIDS assay involves 
quantification of mRNA levels of 14 target genes (HOXA7, AURKA, NEK2, FOXM1B, CCNB1, 
CEP55, CENPA, DNMT3B, DNMT1, HELLS, MAPK8, BMI1, ITGB1 and IVL) and 2 reference genes 
(YAP1 and POLR2A). We setup and run the qMIDS assay at our laboratory in Guiyang, School of 
Stomatology, Guizhou Medical University. In order to obtain data comparable to previous European 
data [11], we adhered tightly to the original qMIDS assay protocol for reverse transcription and 
quantitative PCR (qPCR) procedures as described previously [11]. qPCR reactions were setup in 
96-well format (see supplemental Figure S1) and run on a Bio-Rad CFX ConnectTM Real Time 
System (Bio-Rad Life Science Research and Development Co., Ltd., Shanghai, China). Relative 
expression data for each target gene against the two reference genes were obtained using the 
Bio-Rad CFX manager 3.0 software. Relative expression data were then exported into Microsoft 
Excel for calculation of qMIDS score based on its original qMIDS algorithm [11]. Due to the tiny tissue 
size (1 mm3) used for each qMIDS assay and direct extraction of mRNA (rather than total RNA), 
quantification of mRNA yield was not accurate by neither spectrophotometer (eg., NanoDrop) nor 
fluorescence dye (eg., PicoGreen). Hence, data quality for each specimen was directly determined 
by qPCR based on the ability to measure both reference genes (YAP1 and POLR2A). Samples that 
failed one or both reference genes were omitted from the study.  
 
Statistical analysis 
For comparison, qMIDS scores from the European study (data extracted from[11]) and the current 
Chinese data were analysed in R (version 2.13.1; The R Foundation for Statistical Computing) and 
plotted using Beeswarm Boxplot software package [13]. Diagnostic test performance between the 
European and Chinese data were compared at a specific qMIDS cut-off at 4.0 which was previously 
found to give the lowest false-positive rate and highest detection rate/sensitivity [11]. Diagnostic test 
efficiency comparison data were calculated using a Diagnostic Test Calculator freeware [14]. The 
qMIDS diagnostic assay efficiency tests were performed according to the STARD Initiative 
recommended protocol [15]. The qMIDS scores were also examined in relation to gender, age, 
differentiation status, tumour staging and lymphatic metastasis status, using the statistical package 
SPSS version 14.0. Kruskal-Wallis analysis was used to test the differentiation of the qMIDS scores 
among the three groups (normal mucosa, tumour margin and core HNSCC). The qMIDS scores of 
HNSCC were further examined using Student-t test for any relationships between the above 
mentioned clinical features using Student’s test. P<0.05 was considered statistically significant. 
 
Results 
This study performed qMIDS assay on 68 Chinese head and neck tissue specimens. The normal 
group had 18 subjects donating normal oral mucosa tissues. The HNSCC patients donated 50 
tumour core HNSCC tissues and 6 of these with additional adjacent tumour margin tissues. These 
tissues were originated from the tongue (n=20, 45.5%), gingival (n=8, 18.2%) buccal mucosa (n=4, 
9.1%), lip mucosa (n=3, 6.8%), floor of mouth (n=3, 6.8%), and other parts of the head and neck (n=6, 
13.6%). The median ± SD qMIDS scores for the Chinese cohort were 1.13 ± 0.66, 4.02 ± 1.66 and 
5.83 ± 3.13 for healthy mucosa tissue, adjacent tumour margin and core HNSCC tumour tissue, 
respectively. For comparison, qMIDS scores were extracted from the European study [11] (dysplasia 
and lichen planus cohorts were excluded as these were not recruited in the Chinese cohort) whereby 
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the median ± SD qMIDS scores were 1.50 ± 0.88, 1.70 ± 1.56 and 6.40 ± 2.11 for healthy mucosa 
tissues (Norway n=61), adjacent tumour margins (UK, n=64) and core HNSCC tumour tissue (UK, 
n=103), respectively (Figure 1). 
 
The Chinese normal oral mucosa samples showed slightly lower qMIDS scores compared to the 
normal samples from Europe. Both the Chinese and European samples were showing highly 
significant segregation of qMIDS scores between normal and tumour samples, respectively. Unlike 
the European cohort, the Chinese adjacent tumour margin samples showed significant 2.4-fold 
higher scores when compared to the normal samples. Based on the previous European study [11], 
an optimum cut-off score value was at 4.0. This cut-off value was therefore used in the current study 
to calculate and compare the diagnostic test efficiency for qMIDS assay on the two cohorts (Figure 
2A). The normal samples were grouped together with tumour margin samples as disease free group 
for the diagnostic test efficiency calculation. Overall, the diagnostic efficiency data between the 
Chinese and European cohorts was highly comparable (Figure 2B). 
 
Further analysis of clinicopathological features within the Chinese HNSCC samples (n=44), we found 
no differences between gender or age, which were in agreement with the European data. Statistically 
significant differences were found when HNSCC samples were segregated into differentiation status, 
tumour staging and lymphatic metastasis (Table 2). These findings were similar to previous 
European data whereby qMIDS scores were inversely correlated with differentiation status of 
HNSCC and were not significantly affected by gender and age [11]. We have previously established 
that HPV status did not affect qMIDS scores in neither HNSCC nor vulva SCC samples (data not 
shown) hence it was not further investigated. As habits such as smoking and drinking are well 
established as risk factors for HNSCC, due to the scarcity of patient records for risk factors, we were 
unable to analyse the correlation between habits and qMIDS scores.  
 
Discussion 
For many cancer types, especially HNSCC, tumour heterogeneity has been a key problem that 
eluded clinicians whereby histopathological findings could not provide a quantitative and objective 
correlation with tumour aggressiveness [8, 16]. To resolve this issue, we have previously developed 
a molecular method, the qMIDS assay [11], by exploiting the aberrant expression of a key oncogene 
FOXM1 shown to be amongst the top upregulated oncogenes across 39 cancer types and is a major 
predictor of poor cancer prognosis [12]. We and others have previously confirmed that FOXM1 is one 
of the top oncogene in HNSCC [11, 17-24]. We have previously published our bioinformatics 
meta-analysis on across over 40 different human cancer types available in Oncomine and NCBI’s 
Gene Expression Omnibus (GEO) databases, showing that FOXM1 is one of the top oncogenes in 
HNSCC [18, 21].  
 
Due to the heterogeneity found in many cancer types including HNSCC, using a single gene as a 
biomarker is unlikely to be accurate for quantifying tumour aggressiveness. To improve diagnostic 
accuracy and specificity, the qMIDS assay had been designed to quantify mRNA levels of 14 
FOXM1-associated genes (HOXA7, AURKA, NEK2, FOXM1B, CCNB1, CEP55, CENPA, DNMT3B, 
DNMT1, HELLS, MAPK8, BMI1, ITGB1 and IVL) involved in the regulation of cell proliferation [25], 
differentiation [17], ageing [26], genomic instability [16, 18, 24, 27, 28], epigenetic [18, 20] and stem 
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cell reprogramming [17, 29-31] as a collective basis to measure cancer aggressiveness via an 
algorithm to compute a malignancy index [11]. The qMIDS test was originally validated in the UK 
involving 256 Caucasian (from UK and Norway) and 36 South Asian (resided in the UK) patients. The 
assay was found to be a practical, sensitive, objective, and quantitative method for detecting not only 
for HNSCC, but also applicable for vulva and skin squamous cell carcinomas [11]. We had also 
previously shown in the Norwegian retrospective study with 19 years of HNSCC survival data that 
qMIDS score was significantly correlated with tumour aggressiveness [11] thereby providing a 
method for quantitative diagnosis and objective stratification of cancer aggressiveness. 
 
Previous studies have reported that geographical, lifestyle and ethnic differences can impact on 
genetic/molecular pathways in head and neck squamous cancers [32-37]. Majority of these studies 
investigated genetic DNA polymorphisms but none of them, to our knowledge, compared gene 
expression levels in HNSCC. We are presenting the first study comparing different ethnic groups and 
gene expression levels in HNSCC using a FOXM1-based cancer diagnostic system [11]. Although 
the 14 genes used in the qMIDS assay were fundamental genes regulating squamous cell carcinoma, 
it was not clear if environmental factors (food, cultural & geographical variations, etc.) coupled with 
differences in ethnicity may impact on molecular differences in HNSCC that render the qMIDS test 
invalid. Given that the HNSCC patients tested previously constituted mainly of ethnic Caucasians 
(~86%) and South Asians (~14%) whereby all the patient samples were obtain either in the UK or 
Norway, we therefore aimed to further validate the qMIDS test to involve an entirely distinct ethnicity 
located in another geographic continent and have the assay independently set up and run in a 
different laboratory using different instruments (but using the same reagents). For this purpose, we 
recruited a total of 68 ethnic Chinese participants of whom, 50 were HNSCC patients and 18 were 
healthy individuals. All participants in this study were residence of Guizhou Province in China. The 
results obtained from this study on Chinese specimens were highly comparable to previously 
published European (UK and Norway) cohort [11]. Using the previously determined optimum cut-off 
score at 4.0 [11], overall diagnostic test efficiency was found to be almost identical between the 
Chinese and European datasets. 
 
We have previously shown that the qMIDS assay had a detection rate of 90-94% and false positive 
rate of 1.3-3.2% on the European patients [11]. These data were consistent with the current study on 
Chinese patients. We had previously demonstrated that qMIDS was able to differentiate between 
benign (low risk) lesions such as oral lichen planus or fibro-epithelial polyps with premalignant (high 
risk) oral dysplastic samples [11], due to scarcity of Chinese patients with premalignant oral lesions 
(probably due to lack of self-awareness on oral diseases and patients were generally of lower social 
economic status), unfortunately we did not get sufficient number of these lesions for investigation. 
We are currently investigating the use of qMIDS as a tool for early oral premalignant cancer risk 
stratification. 
 
In addition to HNSCC diagnosis, we previously demonstrated another clinical utility for qMIDS in 
tumour margin analysis whereby a 2D molecular topology of resolution down to 1 mm could be 
reconstructed using qMIDS on surgical samples. This was possible because each qMIDS test 
requires only a minute 1-2 mm tissue sample for analysis [11]. Although we did not carry out similar 
tumour margin analysis, the present study found a notable 2.4-fold higher qMIDS score in the 
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Chinese adjacent tumour margin tissues compared to that of the European. This could be due to 
confounding factors such as error in pathological classification of the tissue samples and/or 
differences in width of surgical margins used. Although the difference was found to be statistically 
significant, the Chinese sample size was small (n=6) and therefore caution in interpretation should be 
exercised here for the adjacent tumour margin group. Due to the sensitivity of qMIDS test, it is not 
surprising that some of these tumour margin samples did contain malignant cells that escaped 
detection by pathologists. Further study involving larger sample size with patient follow up may 
potentially reveal a relationship between qMIDS-positive tumour margins and tumour recurrence. 
 
Similar to histopathology, qMIDS also involves testing tissue biopsy samples and hence it remains 
invasive and prone to mis-sampling issues. However, as field change is a common phenomenon in 
HNSCC [38-40] and that qMIDS detects molecular changes (mRNA expression) that precedes 
phenotypic change (protein and structural alterations), the sensitivity of detecting pathological genetic 
change in a given sample would arguably be much higher than that of histopathology which relies 
solely on visualising protein and structural change. Furthermore, dysplastic phenotype is often 
missed or misinterpreted when examining histopathological slides because molecular changes 
indicative of malignant conversion do not necessarily produce clinically or histopathologically 
detectable changes [38, 39]. Hence, given that qMIDS detects molecular changes, it would be more 
resistant to sampling issues (considering oral field changes) compared to histopathology. 
 
Current clinicopathological features are unable to predict tumour aggressiveness [41-43]. As a result, 
current practise is that most patients with oral premalignant disorders (OPMD) are indiscriminately 
put on time consuming, costly and stressful surveillance [42, 43]. Such “waiting game” creates 
unnecessary anxiety and stress for majority (88%) of low risk patients whilst delaying and 
under-treating minority (12%) of high risk patients [44]. A systematic review estimated a malignancy 
conversion rate for OPMD is 12% [44]. Given 135,100 HNSCC cases in China each year [4], and 70% 
of HNSCC preceded by OPMDs [45], the estimated total number of OPMDs would therefore be over 
788,000 cases/year. Most patients only return when tumours have grown to advance stages when it 
is difficult to treat or untreatable. Delayed treatment thereby directly causes poor long-term morbidity 
and survival [7, 8, 16, 42, 43]. The current lack of a ‘case-finding’ diagnostic test results in ineffective 
patient management and unnecessary long-term financial burden to both patients and healthcare 
establishments. With a molecular test such as qMIDS, we have shown promising results previously 
that qMIDS was able to detect malignant cells in otherwise clinicopathologically “normal-looking” 
biopsy tissue [11] and therefore we are currently investigating the clinical use of qMIDS for 
identification of premalignant lesions. 
 
In summary, this study provided the first evidence that the pathophysiology of HNSCC was 
molecularly (at mRNA levels) very similar between the Chinese and European specimens. 
Furthermore, it reiterates that the qMIDS assay robustly measures a universal oncogenic program 
driven by FOXM1, at least in HNSCC, which transcends ethnicity, age, gender and geographic 
origins. A high throughput, cost-effective and robust test such as qMIDS may play an important role 
for quantitative diagnosis of ambiguous biopsy specimens and/or to provide an objective diagnosis 
based on digital molecular profile to avoid mis-diagnosis. Given that majority (88%) of oral lesions are 
benign [44], identifying 12% of high risk potentially malignant oral lesions is notoriously difficult 
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[41-43]. Further study involving testing oral premalignant lesions with qMIDS and long-term 
correlation with follow-up study would enable the qMIDS test to be used as an early cancer test.  
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Figure Legends 
 
Figure 1. Comparison of qMIDS scores between Chinese and European head and neck tissue 
samples. Data were plotted as dot-plot with box-and-whisker overlays (median and 25-75% 
percentiles). An optimum cut-off at 4.0 was found previously based on the European samples[11]. 
Statistical Student-t tests were performed between sample groups and corresponding P values were 
as indicated within the figure.  
 
Figure 2. qMIDS Diagnostic test efficiency comparison between Chinese and European cohorts. A, 
Cohort analysis for Chinese (n=68) and European (n=228, consisting of UK and Norwegian 
participants, data were extracted from previous publication[11]). Calculations were based on cut-off 
score at 4.0 and statistical results are compared in panel B.  
 
 
Supplementary Figure Legends 
 
Figure S1. qMIDS 96-well assay format and protocols. A, qMIDS assay layout for 2 samples in 
duplicates. B, qPCR reaction composition per well. qMIDS standards consist of a mixture of all 16 
biomarker templates at fixed concentration to give a final concentration of 105 copies/well. C, Master 
mix preparation for each sample. D, Primer (Step 1) and master mix (Step 2) loading procedures, and 
qPCR cycling protocol (Step 3). 
Table 1: qMIDS Scores and Clinicopathological Features of Chinese HNSCC (n=44) 
Clinical 
Features 
Groups N Mean* SD** t P*** 
Gender Male Female 
24 
20 
6.46 
7.27 
3.23 
3.04 0.85 0.40 
Age <60 >60 
13 
31 
6.95 
6.78 
2.86 
3.28 0.17 0.87 
Differentiation 
Status 
High 
Moderate/Poor 
32 
12 
5.44 
10.55 
1.96 
2.61 7.04 1x10
-8 
Tumour 
Staging 
I and II 
III and IV 
35 
9 
5.88 
10.55 
2.39 
3.01 4.89 1x10
-5 
Lymphatic 
Metastasis 
No 
Yes 
34 
10 
5.76 
10.47 
2.32 
2.85 5.36 3x10
-6 
*Mean qMIDS score; ** SD = standard deviation; ***P values in bold are highly significant P>0.001. 
 
 
 
 
 


